Evidence map›Paper›PMID 27626165›Full record

ArticleOncotarget2016

Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.

Seung-Hyun Jung, Min Sung Kim, Chan Kwon Jung, Hyun-Chun Park, So Youn Kim, Jieying Liu, Ja-Seong Bae, Sung Hak Lee, Tae-Min Kim, Sug Hyung Lee and 1 more

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Guideline
  2. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.Thyroid : official journal of the American Thyroid Association · 2019
    Pooled it
  3. Review
  4. Article
  5. Thyroid Nodule Sphericity Metrics Discriminate Benign and Malignant Follicular and Oncocytic Neoplasms.Thyroid : official journal of the American Thyroid Association · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Seung-Hyun JungDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Min Sung KimDepartment of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chan Kwon JungDepartment of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyun-Chun ParkDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
So Youn KimDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jieying LiuDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ja-Seong BaeDepartment of General Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sung Hak LeeDepartment of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Tae-Min KimDepartment of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sug Hyung LeeDepartment of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yeun-Jun ChungDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Catholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular thyroid adenoma (FTA) precedes follicular thyroid carcinoma (FTC) by definition with a favorable prognosis compared to FTC. However, the genetic mechanism of FTA to FTC progression remains unknown. For this, it is required to disclose FTA and FTC genomes in mutational and evolutionary perspectives. We performed whole-exome sequencing and copy number profiling of 14 FTAs and 13 FTCs, which exhibited previously-known gene mutations (NRAS, HRAS, BRAF, TSHR and EIF1AX) and copy number alterations (CNAs) (22q loss and 1q gain) in follicular tumors. In addition, we found eleven potential cancer-related genes with mutations (EZH1, SPOP, NF1, TCF12, IGF2BP3, KMT2C, CNOT1, BRIP1, KDM5C, STAG2 and MAP4K3) that have not been reported in thyroid follicular tumors. Of note, FTA genomes showed comparable levels of mutations to FTC in terms of the number, sequence composition and functional consequences (potential driver mutations) of mutations. Analyses of evolutionary ages using somatic mutations as molecular clocks further identified that FTA genomes were as old as FTC genomes. Whole-transcriptome sequencing did not find any gene fusions with potential significance. Our data indicate that FTA genomes may be as old as FTC genomes, thus suggesting that follicular thyroid tumor genomes during the transition from FTA to FTC may stand stable at genomic levels in contrast to the discernable changes at pathologic and clinical levels. Also, the data suggest a possibility that the mutational profiles obtained from early biopsies may be useful for the molecular diagnosis and therapeutics of follicular tumor patients.

Indexed as

MutationAdenocarcinoma, FollicularAdenomaAdultAgedDNA Copy Number VariationsFemaleGene FusionGenomeHumansMaleMiddle AgedThyroid Neoplasmscopy number alterationfollicular thyroid adenomafollicular thyroid carcinomamutationstumor progression

Identifiers

PMID27626165
PMCPMC5342504
OpenAlexW2510202098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.